Harshad Amin
Boca Raton Regional Hospital(US)BRCR Global (United States)(US)
Publications by Year
Research Areas
Acute Myeloid Leukemia Research, Lipoproteins and Cardiovascular Health, Cardiac, Anesthesia and Surgical Outcomes, Cardiac pacing and defibrillation studies, Acute Lymphoblastic Leukemia research
Most-Cited Works
- → High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections(2021)191 cited
- → Relation of Cardiac Troponin I Levels With In-Hospital Mortality in Patients With Ischemic Stroke, Intracerebral Hemorrhage, and Subarachnoid Hemorrhage(2008)102 cited
- → Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study(2023)77 cited
- → Incidence of perioperative myocardial infarction and of 2-year mortality in 577 elderly patients undergoing noncardiac vascular surgery treated with and without statins(2009)64 cited
- → Cardiovascular Manifestations in Patients With Thrombotic Thrombocytopenic Purpura: A Single‐center Experience(2010)43 cited
- → Effect of Beta Blockers, Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers, and Statins on Mortality in Patients With Implantable Cardioverter-Defibrillators(2008)24 cited
- → Statins Reduce Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Failure and Combined Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy(2009)24 cited
- → Prevalence of transthoracic echocardiographic abnormalities in patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage(2010)22 cited
- → Incidence of Appropriate Cardioverter-Defibrillator Shocks and Mortality in Patients With Heart Failure Treated With Combined Cardiac Resynchronization Plus Implantable Cardioverter-Defibrillator Therapy Versus Implantable Cardioverter-Defibrillator Therapy(2009)21 cited
- → Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)(2020)21 cited